IP Library Granted Patent US 12662481
Granted Patent B2
US 12662481 · App. 17/580,207 · Granted Jun 23, 2026

Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors

Inventors: Sheldon N. Crane (Notre Dame de I'lle Perrot, CA); Vouy-linh Truong (Pierrefonds, CA); Abbas Abdoli (Montreal, CA); Jean-François Truchon (Saint-Laurent, CA); Cameron Black (Baie-D'Urfé, CA); Stéphane Dorich (Point-Claire, CA); Lee Fader (Hawkesbury, CA); Stéphanie Lanoix (Mansfield, CA); Paul Jones (Verdun, CA); Miguel St-Onge (Vaudreuil-Dorion, CA); Audrey Picard (Mirabel, CA); Cyrus M. Lacbay (Montreal, CA)
Assignee: Repare Therapeutics Inc.
C07D471/04A61P35/00C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12662481
App. No.
17/580,207
Granted
Jun 23, 2026
Kind
B2
Abstract

Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.

Claims (31)

1 . A compound of formula (I):

or a pharmaceutically acceptable salt thereof,

wherein

is a double bond, and each Y is independently N or CR 4 ; or is a single bond, and each Y is independently NR Y , carbonyl, or C(R Y ) 2 ; wherein each R Y is independently H or optionally substituted C 1-6 alkyl;

R 1 is methyl;

R 3 is optionally substituted C 1-9 heteroaryl or optionally substituted C 1-9 heteroaryl C 1-6 alkyl;

each R 4 is independently hydrogen, halogen, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, or optionally substituted C 2-6 alkynyl; and

X is hydrogen or halogen.

2 . The compound of claim 1 , wherein the compound is a compound of formula (II):

or a pharmaceutically acceptable salt thereof.

3 . The compound of claim 1 , wherein the compound is a compound of formula (IB):

or a pharmaceutically acceptable salt thereof.

4 . The compound of claim 1 , wherein the compound is a compound of formula (IB-a):

or a pharmaceutically acceptable salt thereof.

5 . The compound of claim 1 , wherein R 3 is optionally substituted, monocyclic C 1-9 heteroaryl comprising at least one nitrogen atom.

6 . The compound of claim 1 , wherein R 3 is:

7 . The compound of claim 1 , wherein R 4 is hydrogen.

8 . The compound of claim 1 , wherein X is hydrogen.

9 . A compound selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

10 . The compound of claim 9 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

11 . The compound of claim 9 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

12 . The compound of claim 9 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

13 . The compound of claim 9 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

14 . The compound of claim 9 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

15 . A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.